P
Paul B. Fisher
Researcher at Virginia Commonwealth University
Publications - 486
Citations - 35304
Paul B. Fisher is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 80, co-authored 449 publications receiving 31149 citations. Previous affiliations of Paul B. Fisher include Discovery Institute & Columbia University Medical Center.
Papers
More filters
Journal ArticleDOI
Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells
Swadesh K. Das,Upneet K. Sokhi,Sujit K. Bhutia,Belal Azab,Zhao-zhong Su,Devanand Sarkar,Paul B. Fisher +6 more
TL;DR: Targeted overexpression of hPNPaseold-35 might provide an effective therapeutic strategy for miR-221–overexpressing and IFN-resistant tumors, such as melanoma.
Journal ArticleDOI
mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src
TL;DR: Using a clinically relevant human melanoma model, it is demonstrated that mda-9/syntenin physically interacts with c-Src and this communication correlates with an increase in FAK/c-SRC complex formation and c- Src activation, leading to enhanced tumor cell invasion and metastatic spread.
Journal ArticleDOI
mda-9/Syntenin : A positive regulator of melanoma metastasis
Habib Boukerche,Zao-Zhong Su,Luni Emdad,Patrick Baril,Brigitte Balme,Luc Thomas,Aaron Randolph,Kristoffer Valerie,Devanand Sarkar,Paul B. Fisher +9 more
TL;DR: Based on its ability to directly alter metastasis, mda-9/syntenin provides a promising new focus for melanoma cancer research with potential therapeutic applications for metastatic diseases.
Journal ArticleDOI
RaSH, a rapid subtraction hybridization approach for identifying and cloning differentially expressed genes
TL;DR: The RaSH approach represents an efficient methodology for identifying and cloning genes displaying differential expression that associate with and potentially regulate complex biological processes.
Journal ArticleDOI
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Margaret A. Park,Clint Mitchell,Guo Zhang,Adly Yacoub,Jeremy C. Allegood,Dieter Häussinger,Roland Reinehr,Andrew C. Larner,Sarah Spiegel,Paul B. Fisher,Christina Voelkel-Johnson,Besim Ogretmen,Steven Grant,Paul Dent +13 more
TL;DR: Induction of cytosolic Ca(2+) by sorafenib and vorinostat is a primary event that elevates dihydroceramide levels, each essential steps in ROS generation that promotes CD95 activation.